Abattis Bioceuticals Corp.
ATTBF · OTC
9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | |
|---|---|---|---|---|
| Market Cap | $11,275 | $57,586 | $28,906 | $6,233 |
| - Cash | $2,019 | $4,064 | $526 | $38 |
| + Debt | $1,569 | $0 | $0 | $31 |
| Enterprise Value | $10,825 | $53,522 | $28,380 | $6,226 |
| Revenue | $357 | $8 | $0 | $0 |
| % Growth | 4,163.2% | – | – | – |
| Gross Profit | $241 | $6 | $0 | $0 |
| % Margin | 67.6% | 77.4% | – | – |
| EBITDA | -$2,903 | -$17,336 | -$5,337 | -$2,132 |
| % Margin | -813.3% | -207,095.9% | – | – |
| Net Income | -$3,042 | -$78,013 | -$7,634 | -$2,339 |
| % Margin | -852.4% | -931,940.1% | – | – |
| EPS Diluted | -0.007 | -0.24 | -0.051 | -0.025 |
| % Growth | 97.3% | -367.8% | -108.5% | – |
| Operating Cash Flow | $9,412 | -$8,279 | -$1,222 | -$733 |
| Capital Expenditures | -$5,061 | -$234 | -$431 | -$46 |
| Free Cash Flow | $4,351 | -$8,513 | -$1,653 | -$779 |